Close
Courage over Cancer Filtered Blog
NIH grant to boost ovarian cancer drug development
The Mays Cancer Center and Evestra Inc., a San Antonio, Texas-based biopharmaceutical company, have been awarded a five-year, $3.3 million Academic Industry Partnership grant from the National Institutes of Health.
Read more
Boosting Hispanic representation in cancer research
The Mays Cancer Center has been named a founding partner of the Advancing Inclusive Research Site Alliance, a coalition of clinical research sites seeking to advance the representation of diverse patient populations in clinical trials.
Read more
Disparities discussed at San Antonio Breast Cancer Symposium
Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.
Read more
Cryo-EM technology brings the study of tumors to a molecular level
UT Health San Antonio is investing $5 million over the next three years in cryo-electron microscopy technology that will help investigators of the Mays Cancer Center study tumors and help researchers of the Greehey Children’s Cancer Research Institute to study childhood cancers.
Read more
New discovery: Compounds that target enzyme, MAP4K3
Daruka Mahadevan, MD, PhD, division chief, hematology-oncology, director of the Institute of Drug Development and associate director for clinical research at Mays Cancer Center at UT Health San Antonio and his team have identified a series of small molecule compounds that target an enzyme, MAP4K3, important to amino acid signaling in autophagy, impacting neurologic diseases and cancer.
Read more
New discoveries in pediatric cancer research
The findings from recent research studies in pediatric cancer offer hope for drug development.
Read more